Oncolytic Virus Therapy Against Cancer
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (31 May 2020) | Viewed by 32983
Special Issue Editor
Special Issue Information
Dear Colleagues,
Recent developments in research into viruses’ capability to destroy cancer cells have shown that oncolytic virotherapy has the potential to become a sustainable alternative to existing therapies. Using a self-amplifying antitumor agent that selectively replicates in cancer cells and avoids destroying healthy tissue offers obvious therapeutic advantages. Several directions of research are underlying this approach. A number of viruses were shown to pose an intrinsic tumor tropism, making their use straightforward in cancer therapy. However, the modifications of viruses to target specific cancer types significantly expands the arsenal of agents capable of fighting tumors. Research aiming to improve viral anticancer efficacy and to extend the therapeutic potential are major topics in oncolytic virotherapy. Engineering viral constructs or devising new viral formulations capable of escaping the surveillance of the immune system is a continuous undertaking for further development of all oncolytic viruses. A major benefit of the use of viruses is the immunotherapeutic effect associated with infection, and multiple strategies are used to amplify this immune response targeted at cancer cells.
This Special Issue aims to offer an overview of these current progresses made in the development of oncolytic viruses to target various types of cancers.
Dr. Mihnea Bostina
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.